Abstract:Background Maintenance of cancer stem-like cell (CSC) stemness supported by aberrantly regulated cancer cell metabolism is critical for CSC self-renewal and tumor progression. As a key glycolytic enzyme, hexokinase 2 (HK2) plays an instrumental role in aerobic glycolysis and tumor progression. However, whether HK2 directly contribute to CSC stemness maintenance in small cell lung cancer (SCLC) is largely unclear. In this study, we aimed to investgate whether HK2 independent of its glycolytic activity is directly involved in stemness maintenance of CSC in SCLC. Methods Immunoblotting analyses were conducted to determine the expression of HK2 in SCLC CSCs and their differentiated counterparts. CSC-like properties and tumorigenesis of SCLC cells with or without HK2 depletion or overexpression were examined by sphere formation assay and xenograft mouse model. Immunoprecipitation and mass spectrometry analyses were performed to identify the binding proteins of CD133. The expression levels of CD133-associated and CSC-relevant proteins were evaluated by immunoblotting, immunoprecipitation, immunofluorescence, and immunohistochemistry assay. RNA expression levels of Nanog, POU5F1, Lin28, HK2, Prominin-1 were analyzed through quantitative reverse transcription PCR. Polyubiquitination of CD133 was examined by in vitro or in vivo ubiquitination assay. CD133(+) cells were sorted by flow cytometry using an anti-CD133 antibody. Results We demonstrated that HK2 expression was much higher in CSCs of SCLC than in their differentiated counterparts. HK2 depletion inhibited CSC stemness and promoted CSC differentiation. Mechanistically, non-mitochondrial HK2 directly interacted with CD133 and enhanced CD133 expression without affecting CD133 mRNA levels. The interaction of HK2 and CD133 promoted the binding of the deubiquitinase ubiquitin-specific protease 11 (USP11) to CD133, thereby inhibiting CD133 polyubiquitylation and degradation. HK2-mediated upregulation of CD133 expression enhanced the expression of cell renewal regulators, SCLC cell stemness, and tumor growth in mice. In addition, HK2 expression was positively correlated with CD133 expression in human SCLC specimens, and their expression levels were associated with poor prognosis of SCLC patients. Conclusions These results revealed a critical non-metabolic function of HK2 in promotion of cancer cell stemness. Our findings provided new insights into the multifaceted roles of HK2 in tumor development.

SALL4 Promotes Gastric Cancer Progression Via Hexokinase II Mediated Glycolysis

SALL4 Activates TGF-beta/SMAD Signaling Pathway to Induce EMT and Promote Gastric Cancer Metastasis

The Invasion and Metastasis of Colon Adenocarcinoma (COAD) Induced by SALL4

SALL4, a Novel Marker for Human Gastric Carcinogenesis and Metastasis.

SALL4 promotes angiogenesis in gastric cancer by regulating VEGF expression and targeting SALL4/VEGF pathway inhibits cancer progression

Sall4 Promotes Glycolysis And Chromatin Remodeling Via Modulating Hp1 Alpha-Glut1 Pathway

Targeting SALL4 by Entinostat Inhibits the Malignant Phenotype of Gastric Cancer Cells by Reducing EMT Signaling

SALL4 promotes glycolysis and chromatin remodeling via modulating HP1α-Glut1 pathway

MAPK4 Silencing in Gastric Cancer Drives Liver Metastasis by Positive Feedback Between Cancer Cells and Macrophages.

Sall4 is A New Target in Endometrial Cancer

Up-Regulation Of Sall4 Is Associated With Survival And Progression Via Putative Wnt Pathway In Gastric Cancer

Sall4, a Stem Cell Factor, Promotes Chemoresistance by Regulates the Side Population Cell Phenotype.

The hsa_circ_0024183 may affects glioblastoma progression by interacting with the protooncogene SALL4

VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling

Inhibition of SALL4 Suppresses Carcinogenesis of Colorectal Cancer Via Regulating Gli1 Expression.

SALL4 promotes cancer stem-like cell phenotype and radioresistance in oral squamous cell carcinomas via methyltransferase-like 3-mediated m6A modification

SALL4: an emerging cancer biomarker and target.

The Expression of SALL4 in Patients with Gliomas: High Level of SALL4 Expression is Correlated with Poor Outcome

Inhibition of SALL4 Reduces Tumorigenicity Involving Epithelial-Mesenchymal Transition Via Wnt/β-catenin Pathway in Esophageal Squamous Cell Carcinoma

S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase

A Non‐metabolic Function of Hexokinase 2 in Small Cell Lung Cancer: Promotes Cancer Cell Stemness by Increasing USP11‐mediated CD133 Stability